Hims & Hers Health (NYSE:HIMS) Receives Buy Rating from BTIG Research

BTIG Research reissued their buy rating on shares of Hims & Hers Health (NYSE:HIMS) in a research report released on Tuesday,Benzinga reports. They currently have a $85.00 price objective on the stock.

A number of other equities analysts have also commented on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Truist Financial dropped their price objective on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a report on Monday, August 18th. KeyCorp started coverage on Hims & Hers Health in a report on Tuesday, October 21st. They set a “sector weight” rating for the company. Bank of America increased their price target on shares of Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a report on Tuesday. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Hims & Hers Health in a research report on Tuesday, October 14th. Two investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $43.75.

Hims & Hers Health Price Performance

HIMS opened at $42.67 on Tuesday. The company has a market capitalization of $9.64 billion, a price-to-earnings ratio of 79.02, a PEG ratio of 3.07 and a beta of 2.20. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The firm has a 50-day moving average price of $51.36 and a 200-day moving average price of $50.84. Hims & Hers Health has a twelve month low of $19.15 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.09 EPS for the quarter, meeting analysts’ consensus estimates of $0.09. Hims & Hers Health had a net margin of 6.05% and a return on equity of 26.48%. The company had revenue of $598.98 million for the quarter, compared to analysts’ expectations of $578.99 million. During the same period in the prior year, the company posted $0.32 EPS. Hims & Hers Health’s revenue was up 49.2% compared to the same quarter last year. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities analysts expect that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Activity at Hims & Hers Health

In other news, insider Patrick Harrison Carroll sold 10,021 shares of the firm’s stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $506,060.50. Following the sale, the insider owned 169,940 shares in the company, valued at approximately $8,581,970. This trade represents a 5.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Michael Chi sold 900 shares of Hims & Hers Health stock in a transaction on Friday, October 10th. The stock was sold at an average price of $58.25, for a total transaction of $52,425.00. Following the sale, the insider directly owned 291,439 shares of the company’s stock, valued at $16,976,321.75. This represents a 0.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 1,372,271 shares of company stock valued at $71,014,785. Company insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds have recently added to or reduced their stakes in HIMS. Invesco Ltd. increased its position in shares of Hims & Hers Health by 502.2% during the 2nd quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock valued at $127,237,000 after purchasing an additional 2,128,587 shares during the last quarter. Nuveen LLC purchased a new stake in Hims & Hers Health in the first quarter worth approximately $58,403,000. Clear Street LLC bought a new position in Hims & Hers Health during the second quarter valued at approximately $83,582,000. Norges Bank purchased a new position in shares of Hims & Hers Health during the second quarter worth approximately $78,464,000. Finally, Marex Group plc bought a new stake in shares of Hims & Hers Health in the 2nd quarter worth approximately $53,626,000. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.